ClinicalTrials.gg
CompletedNCT05721729Updated Dec 18, 2025

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

A Phase 2 interventional study of Mizagliflozin and Placebo in Postbariatric Hypoglycemia, sponsored by Vogenx, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Vogenx, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 294 studies in Hypoglycemia with a site in United States — 36 open to participants now, 49 under way, 5 of them phase 3. Hypoglycemia · United States.

Enrollment
158th of 239
15 · median 24
Started
2023
with 12 others
Phase 2
38 of 294
3 open now
Registered
254th of 294
by date

Among the 294 studies in Hypoglycemia with a site in United States, this one is the 158th largest by enrollment of the 239 interventional ones that give a count, is one of 13 that started in 2023, is one of 38 in phase 2, and was the 254th registered.

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Open to participants now

36 of the 294 studies in Hypoglycemia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Hypoglycemia with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.

Read the detailed description

This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions. This study will examine repeat doses of mizagliflozin and placebo while also evaluating dosing regimen. Up to 15 subjects are expected to complete the study. Subjects will be randomly assigned to a treatment arm within a cohort. Each subject should receive placebo and 2 active dose regimens in a crossover fashion.

03

Conditions studied

  • Postbariatric Hypoglycemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Roux-en-Y gastric bypass surgery performed > 6 months prior to enrollment
  • Diagnosis of PBH

Exclusion criteria

Exclusion Criteria:

  • History of current medical conditions (other than PBH) which may result in hypoglycemia such as insulinoma, adrenal insufficiency, insulin hypoglycemia, congenital hyperinsulinemia.
  • Current use of insulin or insulin secretagogues
  • History of current fasting hypoglycemia
  • Pregnancy and/or lactation: For women of : there is a requirement for a negative urine pregnancy test and for agreement to use during the study and for at least 2 weeks after participating in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Once and twice daily dosing will be examined.

    Drug: Mizagliflozin · Drug: Placebo

  • Experimental
    Cohort 2

    Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Twice and three times daily dosing will be examined.

    Drug: Mizagliflozin · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of participants with adverse events

    Time frame: Through study completion, 43 days

  2. Vital Signs

    Number of participants with abnormal vital signs

    Time frame: Through study completion, 43 days

  3. Laboratory Tests

    Number of participants with abnormal laboratory tests

    Time frame: Through study completion, 43 days

  4. Glucose nadir after dosing

    Time course of glucose concentrations during MMTT

    Time frame: 0-3 hours following liquid meal

Secondary outcomes

  1. MMTT peak glucose concentration after dosing

    Time course of glucose concentrations during MMTT

    Time frame: 0-3 hours following liquid meal

  2. MMTT peak insulin concentration after dosing

    Time course of insulin concentrations during MMTT

    Time frame: 0-3 hours following liquid meal

  3. MMTT time to peak glucose concentration after dosing

    Time course of glucose concentrations during MMTT

    Time frame: 0-3 hours following liquid meal

  4. MMTT time to peak insulin concentration after dosing

    Time course of insulin concentrations during MMTT

    Time frame: 0-3 hours following liquid meal

  5. MMTT glucose concentration

    MMTT glucose area under the curve (AUC0-1, AUC0-2, and AUC0-3) after dosing

    Time frame: 0-3 hours following liquid meal

  6. MMTT insulin concentration

    MMTT insulin area under the curve (AUC0-1, AUC0-2, and AUC0-3) after dosing

    Time frame: 0-3 hours following liquid meal

07

Study locations

2 sites
  • Stanford
    Palo Alto, California 94304, United States
  • University of Colorado / Anschutz Medical Campus
    Aurora, Colorado 80045, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in May 2024, 10 months.

Of 24 phase 2 interventional studies under Hypoglycemia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 10, 2023
StartActual
Jun 23, 2023
Primary completionActual
May 1, 2024
CompletionActual
Jun 1, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05721729
Lead sponsor
Vogenx, Inc.
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Jun 23, 2023
Primary completion
May 1, 2024
Completion
Jun 1, 2025
Last update
Dec 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mizagliflozin

Start the discussion